Main phytoderivatives in the management of benign prostatic hyperplasia

P. Marandola, H. Jallous, F. Bombardelli, P. Morazzoni

Research output: Contribution to journalArticlepeer-review


Surgery has been considered the standard treatment of benign prostatic hyperplasia (BPH) in patients with severe obstructive disorders of micturition occurring in the advanced stages of the disease. In early stages, pharmacological therapies (hormonal, non-hormonal, phytoderivatives) capable of improving urological disturbances and of delaying surgery can be of valid help in the management of BPH. Phytoderivatives, containing several active constituents which may exert additive and/or synergistic actions, are reported to be generally well tolerated and to have minimal side effects with a very good risk/benefit ratio.

Original languageEnglish
Pages (from-to)195-204
Number of pages10
Issue number3
Publication statusPublished - 1997


  • Benign prostatic hyperplasia (BPH)
  • Medical treatment
  • Phytotherapy

ASJC Scopus subject areas

  • Pharmacology


Dive into the research topics of 'Main phytoderivatives in the management of benign prostatic hyperplasia'. Together they form a unique fingerprint.

Cite this